Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03384134
Other study ID # 120111 UCI AA #2019-5027
Secondary ID 1R01CA222012-01
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2019
Est. completion date June 30, 2024

Study information

Verified date October 2023
Source University of California, Irvine
Contact Haydee G Cortes, BA
Phone 714-456-2838
Email cortesh@uci.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to examine the feasibility of the ambulatory monitoring protocol, called Pain Buddy, in documenting children's pain, symptoms and quality of life while receiving outpatient chemotherapy. The long term goal of Pain Buddy is to help doctors, nurses, and parents get the information they need to give children treatments for pain and symptom management that work. Using Pain Buddy, we aim to quantify the prevalence and intensity of daily pain and symptom episodes in children at home, data that will be used to develop a psychosocial intervention to be delivered electronically to children at home with a goal of improving quality of life. Secondary aims also include examining children's quality of life pre- and post- Pain Buddy and satisfaction with the use of Pain Buddy. This project has the potential to improve the quality of life of tens of thousands of children suffering from cancer each year using transformative mobile health information technology based approach to pain assessment and management.


Description:

Approximately 12,000 children are diagnosed with cancer in the United States each year and the majority of these children will experience moderate to severe pain and disabling symptoms such as fatigue and nausea during the course of their illness. Survivors of childhood cancer are also at high-risk for long-term chronic pain. Unfortunately, the World Health Organization (WHO) indicates that current efforts to manage pain in pediatric oncology patients are seriously inadequate. Reasons for under treatment of pain and symptoms in children diagnosed with cancer are complex and are likely related to deficits in the process of assessment and management as well as lack of timely access to pharmacological and non-pharmacological interventions. Management of pain in this population is also compounded by the fact that increasing numbers of children currently receive chemotherapy on an outpatient basis due to advances in healthcare and changes in the medical-economical environment. To date, interventions targeting pain and symptom management in the home setting of children suffering from cancer are seriously lacking. To address this significant gap, the candidate is proposing significant training in pediatric cancer pain and symptom management and an innovative two-phase research strategy. The first phase of research will focus on the development and formative evaluation of an innovative handheld electronic program (Pain Buddy) that provides remote monitoring of pain and symptoms and delivery of cognitive and behavioral skills training to children undergoing treatment for cancer. The second phase of this application involves evaluation of the efficacy of the program using a randomized controlled trial design. Pain Buddy will allow for collection of "real time" pain and symptom data that will be transmitted immediately and monitored remotely by the oncology treatment team. Remote symptom monitoring in real time will provide an opportunity for timely implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life. Pain Buddy will also deliver psychosocial skills training, teaching cognitive and behavioral strategies to manage pain and symptom-related distress. The skills training will target coping and self-efficacy in children without the need for face-to-face intervention which is not feasible in the majority of settings. Symptom monitoring and skills training will further increase patient engagement in their own health care, which is a main goal of the Institute of Medicine and many other organizations. The objectives outlined above will be accomplished by the following specific aims: PHASE I: Development and Formative Evaluation Specific Aim 1: Through collaboration with the California Institute for Telecommunications and Information Technology (Calit2), develop and examine the usability of a cognitive and behavioral skills training intervention (Pain Buddy) delivered via electronic, handheld technology in conjunction with a validated pain and symptom assessment protocol (Jacob, E.) that will allow for monitoring of and response to pain and symptoms of pediatric oncology patients in real time. Hypothesis 1. Children and their parents will demonstrate the ability to use Pain Buddy on the electronic device and will rate high levels of acceptability, usability and satisfaction on beta testing. PHASE II: Randomized Controlled Trial of Pain Buddy Specific Aim 2: Using a randomized controlled trial design, we will examine the efficacy of Pain Buddy in managing pain and symptoms in children suffering from cancer. Hypothesis 2. Children enrolled in the Pain Buddy group will report lower symptom-related distress as measured by the Memorial Symptom Assessment Scale (MSAS), compared to children in the monitoring group (primary outcome). Hypothesis 3. Children in the Pain Buddy group will evidence lower pain severity and higher quality of life compared with children in the monitoring group (secondary outcomes). Hypothesis 4. Children and nurses will demonstrate high rates of compliance (85% or greater) with Pain Buddy (secondary outcome). The long-term goals of this research are to develop a usable, engaging electronic decision-support pain and symptom management intervention for children receiving outpatient chemotherapy using Smartphone technology and to examine the efficacy of the electronic decision-support intervention on children's pain and quality of life. These long-term goals will be accomplished through assessment of the data collected from patients, parents and physicians using the ambulatory monitoring protocol. PHASE III: Multi-Site Randomized Controlled Trial of Pain Buddy Primary Aim: Determine if Pain Buddy is more effective than attention control in reducing pain severity among children ages 8-18 years old undergoing outpatient cancer treatment. Secondary Aims: 1. Examine the impact of Pain Buddy on symptom-related distress, health-related quality of life, functional status, and satisfaction with treatment experience. 2. Determine whether baseline characteristics of children (emotional functioning) and parents (stress, attitudes regarding analgesic use for children) moderate the effect of Pain Buddy on pain severity.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria: - Between the ages of 8-18 years - Currently undergoing outpatient treatment for cancer - Patients who are able to speak, read, and write in English. Parents who are able to speak, read, and write in English or Spanish - Have home internet access to use Pain Buddy (the internet will be used to securely send the pain information to the research team). Exclusion Criteria: - Cognitive impairment, such as a developmental delay or mental retardation that would prevent children from being able to use the Pain Buddy program. - Children diagnosed with acute myelogenous leukemia (AML) or acute promyelocytic leukemia (APL) as the treatment protocols for these children are largely inpatient, precluding use of the intervention.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pain Buddy
Pain Buddy is a user interface (application) which contains a personalized avatar (Pain Buddy) to guide children and parents through daily diary entries using mobile devices. The Pain Buddy application has been designed to be used with children age 8-18, receiving outpatient chemotherapy, as well as their parents. Pain Buddy will capture real time pain data from patients and that will ultimately allow for remote monitoring of patient symptoms. Remote symptom monitoring in real time will provide an opportunity for implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life in children with cancer. The use of symptom monitoring and skills training will further increase patient engagement in healthcare.

Locations

Country Name City State
United States University of California, Irvine Orange California

Sponsors (3)

Lead Sponsor Collaborator
University of California, Irvine American Cancer Society, Inc., National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in prevalence and intensity of pain episodes and other distressing physical and psychological symptoms. As part of the daily electronic Pain Buddy diary, children are administered the Memorial Symptoms Assessment Scale. Children 8-9 receive an 8-item instrument and are asked to report frequency (i.e. a very short time, a medium amount, almost all the time) severity (i.e. a little, a medium amount, very), and how distressful (i.e. not at all, a little, a medium amount, very) each symptom was. Children 10-18 receive a 30-item instrument and are asked to report how often (i.e. almost never, sometimes, a lot, almost always), how severe (i.e. slight, moderate, severe, very severe), and how distressful (i.e. not at all, a little bit, somewhat, quite a bit, very much) each symptom was. Baseline and day 60
Primary Changes in pain severity, location, and affective dimensions Child's pain is assessed using the 3 components of the Adolescent Pediatric Pain Tool. 1. Children use a body outline/map to identify areas they are experiencing pain. 2. Children report pain intensity from "not in pain" (score of 0) and "worst pain" (score of 100) using the 100-mm Visual Analog Scale for Pain. 3. Children are presented with a pain quality word descriptor list within 4 categories (Sensory, affective, evaluative, and temporal). Baseline and day 60
Primary Changes in children's quality of life since using Pain Buddy is assessed using the Pediatric Quality of Life Inventory (child self-report, ages 8-12, 13-18; parent report child ages 8-12, 13-18) Children and parents are asked to report on the child's health related quality of life. The measure incorporates a generic, cancer, and fatigue module and asks question on a 5-point likert scale from 0 ("Never") to 4 ("Almost Always") For questions like "I have trouble sleeping." Higher scores on the scale suggest a better health related quality of life. These responses are useful in understanding pain information collected in Pain Buddy. Baseline, day 60, and day 180
Primary Changes in Children's Anxiety and Depression assessed using the Revised Child Anxiety and Depression Scale (RCADS) Parent and Child's self report on 47-item scale with subscales including separation anxiety, social phobia, generalized anxiety, panic disorder, obsessive compulsive disorder, and major depression. Items are rated on a 4-point Likert scale from 0 ("never") to 3 ("always"). Higher scores suggest higher levels of anxiety and depression. Baseline, day 60, and day 180
Primary State-Trait Anxiety Inventory (STAI) (parent self-report) Only the Trait section of the questionnaire is administered to parents to assess their self reported anxiety. Items rated on a 4-point Likert Scale from 1 ("Almost Never") to 4 ("Almost Always"). Higher scores suggest higher levels of anxiety. Baseline
Primary Changes in Perceived Stress (parent self-report) Parents are administered the 14-item Perceived Stress Scale and asked to rate statements such as "In the past month, how often have you been upset because of something that happened unexpectedly?" and "In the past month how often have you felt that things were going your way?" Subjects rate the items on a 5-point Likert-type scale with higher scores reflecting greater perceived stress. Baseline, day 60, and day 180
Primary Medication Attitude Questionnaire (MAQ) (parent self-report) Parents were asked to report their attitudes regarding use of pain medication for treating children's pain. The factors assessed were Appropriate-Use (e.g., "Giving children pain medication for pain teaches proper use of drugs"), Side-Effects (e.g., "Side effects are something to worry about when giving children pain medication"), and Avoidance (e.g., "Pain medication works best if saved for when the pain is quite bad"). Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases